Immunic director files initial ownership report

IMMUNIC, INC. has filed an initial Form 3 ownership report for director Jon Congleton.

Rhea-AI Filing Summary

IMMUNIC, INC. has filed an initial Form 3 ownership report for director Jon Congleton. This filing identifies him as a board member but shows no reported transactions or derivative positions in the data provided. It is a routine regulatory disclosure about insider status.

Key Terms

Form 3, reporting person, ten percent owner

3 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3): initial statement of beneficial ownership"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

reporting person regulatory

""reportingPersons": [{ "name": "Congleton Jon" }]"

ten percent owner regulatory

""is_ten_percent_owner": 0 in the reportingPersons section"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Immunic (IMUX) Form 3 filing by Jon Congleton show?

The Form 3 filing for Immunic (IMUX) identifies Jon Congleton as a director and initial reporting person. It shows no reported stock transactions or derivative holdings in the provided data, indicating a purely administrative ownership registration.

Who is the reporting person in the Immunic (IMUX) Form 3?

The reporting person is Jon Congleton, listed as a director of Immunic, Inc. The Form 3 establishes his insider status with the SEC but, in the available data, does not list any specific security holdings or recent trades.

Does the Immunic (IMUX) Form 3 report any insider stock trades?

No, the Form 3 data for Immunic (IMUX) shows zero buy, sell, gift, exercise, or tax-withholding transactions. It serves as an initial statement of beneficial ownership without recording any trading activity in company securities.

Are any derivative securities disclosed in the Immunic (IMUX) Form 3?

The derivativeSummary section in the Immunic (IMUX) Form 3 is empty. This indicates there are no derivative securities, such as stock options or warrants, reported for director Jon Congleton in this particular filing.

Is Jon Congleton a 10% owner of Immunic (IMUX) according to the Form 3?

According to the Form 3 data, Jon Congleton is identified as a director but not as a ten percent owner. The ten percent owner flag is set to zero, so he is reported in his board capacity rather than as a large shareholder.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/31/2026 - 04:01 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Congleton Jon

(Last) (First) (Middle)

1200 AVENUE OF THE AMERICAS, SUITE 200

(Street)

NEW YORK NEW YORK 10036

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/27/2026

3. Issuer Name and Ticker or Trading Symbol
IMMUNIC, INC. [ IMUX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

No securities are beneficially owned.

No securities are beneficially owned.

	/s/ Jon Congleton	03/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)